CL2021001623A1 - Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer - Google Patents
Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancerInfo
- Publication number
- CL2021001623A1 CL2021001623A1 CL2021001623A CL2021001623A CL2021001623A1 CL 2021001623 A1 CL2021001623 A1 CL 2021001623A1 CL 2021001623 A CL2021001623 A CL 2021001623A CL 2021001623 A CL2021001623 A CL 2021001623A CL 2021001623 A1 CL2021001623 A1 CL 2021001623A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- cdk4
- combination therapy
- treating cancer
- raf
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 229950003687 ribociclib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con una combinación farmacéutica que comprende (a) un inhibidor de Raf como se define en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de CKD4/6, en particular ribociclib, particularmente para utilizar en el tratamiento de una enfermedad proliferativa, con preferencia melanoma o adenocarcinoma ductal pancreático.The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof, and (b) a CKD4/6 inhibitor, in particular ribociclib, particularly for use in the treatment of a proliferative disease, preferably melanoma or pancreatic ductal adenocarcinoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782767P | 2018-12-20 | 2018-12-20 | |
| US201962793128P | 2019-01-16 | 2019-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001623A1 true CL2021001623A1 (en) | 2022-02-11 |
Family
ID=69165429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001623A CL2021001623A1 (en) | 2018-12-20 | 2021-06-17 | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3897591A1 (en) |
| JP (1) | JP2022514056A (en) |
| KR (1) | KR20210105388A (en) |
| CN (1) | CN113453671A (en) |
| AU (1) | AU2019407159A1 (en) |
| BR (1) | BR112021011699A2 (en) |
| CA (1) | CA3123510A1 (en) |
| CL (1) | CL2021001623A1 (en) |
| IL (1) | IL283937A (en) |
| MX (1) | MX2021007477A (en) |
| TW (1) | TW202038964A (en) |
| WO (1) | WO2020128878A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715163B (en) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
| JP7309614B2 (en) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | combination therapy |
| CN113795490A (en) | 2019-05-13 | 2021-12-14 | 诺华股份有限公司 | New crystals of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2(trifluoromethyl)isonicotinamide Form as a Raf inhibitor to treat cancer |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN115551509A (en) * | 2020-05-12 | 2022-12-30 | 诺华股份有限公司 | Therapeutic combinations comprising CRAF inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091876A1 (en) * | 2012-07-26 | 2015-03-04 | Novartis Ag | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US10604786B2 (en) * | 2015-05-20 | 2020-03-31 | Pamgene Bv | Method for predicting the response of melanoma patients to targeted pharmacotherapy |
| WO2017037587A1 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Combination of ribociclib and dabrafenib for treating or preventing cancer |
| JP7309614B2 (en) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | combination therapy |
-
2019
- 2019-12-18 KR KR1020217022093A patent/KR20210105388A/en not_active Ceased
- 2019-12-18 AU AU2019407159A patent/AU2019407159A1/en not_active Abandoned
- 2019-12-18 JP JP2021535501A patent/JP2022514056A/en active Pending
- 2019-12-18 EP EP19836553.8A patent/EP3897591A1/en not_active Withdrawn
- 2019-12-18 MX MX2021007477A patent/MX2021007477A/en unknown
- 2019-12-18 WO PCT/IB2019/060987 patent/WO2020128878A1/en not_active Ceased
- 2019-12-18 CA CA3123510A patent/CA3123510A1/en active Pending
- 2019-12-18 BR BR112021011699-0A patent/BR112021011699A2/en not_active Application Discontinuation
- 2019-12-18 CN CN201980092575.1A patent/CN113453671A/en active Pending
- 2019-12-20 TW TW108147073A patent/TW202038964A/en unknown
-
2021
- 2021-06-13 IL IL283937A patent/IL283937A/en unknown
- 2021-06-17 CL CL2021001623A patent/CL2021001623A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123510A1 (en) | 2020-06-25 |
| WO2020128878A1 (en) | 2020-06-25 |
| IL283937A (en) | 2021-07-29 |
| BR112021011699A2 (en) | 2021-09-08 |
| JP2022514056A (en) | 2022-02-09 |
| MX2021007477A (en) | 2021-08-05 |
| CN113453671A (en) | 2021-09-28 |
| TW202038964A (en) | 2020-11-01 |
| EP3897591A1 (en) | 2021-10-27 |
| AU2019407159A1 (en) | 2021-07-15 |
| KR20210105388A (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001623A1 (en) | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer | |
| CL2023000847A1 (en) | Combination therapy including krasg12c inhibitor and pharmaceutically active agent to treat cancer | |
| MX2017015938A (en) | EZH2 INHIBITORS TO TREAT LYMPHOMES. | |
| MX379297B (en) | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE. | |
| MX2018005315A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER. | |
| MX2017005258A (en) | COMBINED THERAPY FOR TREATMENT OF DISEASE. | |
| AR102553A1 (en) | COMBINATION THERAPY WITH OX40 UNION AGONISTS AND TIGIT INHIBITORS | |
| AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
| CR20170014A (en) | METHODS TO TREAT CANCER WITH TIGIT INHIBITORS AND AGENTS AGAINST CANCER | |
| MX2018006674A (en) | CANCER TREATMENT USING 2-DESOXI-2-FLUORO-L-FUCOSA IN COMBINATION WITH A CONTROL POINT INHIBITOR. | |
| AR101740A1 (en) | COMBINATION AND COMPOSITION THERAPY | |
| MX2016015434A (en) | Pharmaceutical combinations for treating cancer. | |
| MX374749B (en) | COMBINATION THERAPY INCLUDING A TOR KINASE INHIBITOR AND A CYTIDINE ANALOGUE TO TREAT CANCER. | |
| BR112017018964A2 (en) | use of plinabulin and methods to treat brain tumor | |
| MX2019015207A (en) | COMPOUNDS TO TREAT OVARIAN CANCER. | |
| MX2016015437A (en) | COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101. | |
| CO2020001107A2 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| MX393601B (en) | USE OF THE ENHANCING INHIBITOR OF ZESTE HOMOLOGUS 2 (EZH2) COMBINED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR IN THE PREPARATION OF DRUGS TO TREAT TUMORS. | |
| CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
| MX2018016332A (en) | Combination chemotherapies. | |
| CL2020001888A1 (en) | Combination therapy to treat or prevent cancer. | |
| EA202191165A1 (en) | ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER | |
| MX2018014049A (en) | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer. | |
| MX387726B (en) | PHTHALAZINE DERIVATIVES AS PARP1, PARP2 AND/OR TUBULIN INHIBITORS USEFUL FOR THE TREATMENT OF CANCER. | |
| CO2019003865A2 (en) | Therapeutic protein |